
Timothy D. McClure, MD, discusses 2-year PRESERVE trial safety data and 12-month AUA findings linking prostate size to IPSS improvement after focal IRE.
Timothy D. McClure, MD, is an assistant professor of urology at Weill Cornell Medical College in New York, New York.

Timothy D. McClure, MD, discusses 2-year PRESERVE trial safety data and 12-month AUA findings linking prostate size to IPSS improvement after focal IRE.

Timothy D. McClure, MD, offers his thoughts on how future advancements will inform the role for focal therapy in prostate cancer.

Timothy D. McClure, MD, outlines key findings from the PRESERVE trial, which evaluated IRE for prostate tissue ablation in patients with intermediate-risk prostate cancer.

Timothy D. McClure outlines his approach to patient selection with focal therapy as well as how NanoKnife fits into that landscape.

Timothy D. McClure, MD, discusses focal therapy with IRE, specifically highlighting its benefits and limitations compared with other treatment options.